Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sunitinib

sunitinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sunitinib

128 trials tracked of sunitinib: 18 in phase 3 or 4 and 10 with published results. The most-cited published study has 1024 citations.

128Trials tracked
18Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 15 Phase 2 84 Phase 1 9 Other / NA 17
  1. Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) Completed · 1,024 cited
  2. Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Completed · 268 cited
  3. Phase 3 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed · 84 cited
  4. Phase 3 A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Completed · 61 cited
  5. Phase 3 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Completed · 58 cited
  6. Phase 3 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Completed · 45 cited
Show 44 more trials
  1. Phase 3 Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Completed · 38 cited
  2. Phase 4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed · 31 cited
  3. Phase 3 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Completed · 23 cited
  4. Phase 3 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed · 22 cited
  5. Phase 4 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed
  6. Phase 4 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed
  7. Phase 3 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed
  8. Phase 3 Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer Completed
  9. Phase 3 Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer Completed
  10. Phase 3 A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer Completed
  11. Phase 3 A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone Completed
  12. Phase 3 Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer Completed
  13. Phase 2 SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma Completed
  14. Phase 2 A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone Completed
  15. Phase 2 Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. Completed
  16. Phase 2 Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Completed
  17. Phase 2 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed
  18. Phase 2 Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed
  19. Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Completed
  20. Phase 2 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Completed
  21. Phase 2 Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma Completed
  22. Phase 2 A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Completed
  23. Phase 2 Sutent + Taxol for Advanced Esophageal Cancer Completed
  24. Phase 2 Study of SU11248 in Men With Advanced Prostate Cancer Completed
  25. Phase 2 Sunitinib in Refractory Adrenocortical Carcinoma Completed
  26. Phase 2 Sunitinib in Treating Patients With Locally Advanced Bladder Cancer Completed
  27. Phase 2 Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy Completed
  28. Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Completed
  29. Phase 2 Phase II Study of Alternating Sunitinib and Temsirolimus Completed
  30. Phase 2 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed
  31. Phase 2 Phase II Sunitinib Prog Met AIPC Completed
  32. Phase 2 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Completed
  33. Phase 2 Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Completed
  34. Phase 2 Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases Completed
  35. Phase 2 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer Completed
  36. Phase 2 Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma Completed
  37. Phase 2 Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer Completed
  38. Phase 2 Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Completed
  39. Phase 2 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed
  40. Phase 2 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed
  41. Phase 2 Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed
  42. Phase 2 Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer Completed
  43. Phase 2 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed
  44. Phase 2 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma Completed

Showing the 50 most-cited and recently-updated of 128 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
First-line immune checkpoint inhibitors plus anti-angiogenic therapy improve progression-free survival and response rates in advanced RCC
Drug Pipeline Meta-analysis
First-line immune checkpoint inhibitors plus anti-angiogenic therapy improve progression-free survival and response rates in advanced RCC Combination Therapy Shows Better Outcomes for Advanced Renal Cell Carcinoma
This meta-analysis of 4,977 patients found that first-line immune checkpoint inhibitors combined with anti-angiogenic therapy significantly …
A new combination of immune checkpoint inhibitors and anti-angiogenic therapy shows better survival rates than standard treatment for advanc…
Frontiers Aug 24, 2026
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Oncology RCT
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
May 16, 2026
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Oncology Sys. Review
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Frontiers Apr 21, 2026